0000899243-16-028321.txt : 20160831 0000899243-16-028321.hdr.sgml : 20160831 20160831204747 ACCESSION NUMBER: 0000899243-16-028321 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160425 FILED AS OF DATE: 20160831 DATE AS OF CHANGE: 20160831 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aunins John G. CENTRAL INDEX KEY: 0001643756 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 161864399 MAIL ADDRESS: STREET 1: C/O SERES HEALTH, INC. STREET 2: 161 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02472 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2016-04-25 2016-04-27 0 0001609809 Seres Therapeutics, Inc. MCRB 0001643756 Aunins John G. C/O SERES THERAPEUTICS, INC. 215 FIRST STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Technology Officer & EVP Common Stock 2016-04-25 4 S 0 18640 31.94 D 56060 D This line item is not new or revised, but is being reported again solely to gain access to the electronic filing system for filing this amendment. This Form 4 when it was initially filed by the Reporting Person on April 27, 2016 and four Forms 4 filed by the Reporting Person after that date incorrectly stated the date the Reporting Person adopted his 10b5-1 trading plan. This amendment is being filed to correct such date. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2016. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $31.48 to $32.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Thomas J. DesRosier, Attorney-in-fact 2016-08-31